Simulate Any Clinical Scenario with Pinpoint Accuracy
A platform for end to end decision-making in clinical development based on next-generation clinical AI technologies
Use Cases
Supporting Sponsors from Early Clinical Development to Approval
Clinical Development
- Protocol Optimization
- Indication Selection
- TPP
- PTS
- Market Forecasting
- Enrollment Prediction
Business Development
- Search and Evaluation - Many to Few
- Comparative Deep Dive - Few to One
- Asset Diligence & Valuation
- Asset Out-licensing & Disposition
Portfolio Management
- Asset Prioritization
- Asset Synergy and Overlap
- Gaps and Opportunities
Prospectively Validated
Predicting trial results before readout, without sponsor data, with 85% accuracy on the primary endpoint
IMVOKE010:
Randomized phase III study of atezolizumab (atezo) as adjuvant monotherapy after definitive therapy of squamous cell carcinoma of the head and neck (scchn)
-
Simulated Results
-
Actual Results
TROPION-Breast01:
A phase III open-label, randomized study of Dato-DXd versus investigator's choice of chemotherapy (ICC) in participants with inoperable or metastatic HR-positive, HER2-negative breast cancer who have been treated with one or two prior lines of systemic chemotherapy
-
Simulated Results
-
Actual Results
ELOQUENT1
Phase III study of lenalidomide and dexamethasone with or without elotuzumab to treat newly diagnosed, previously untreated multiple myeloma
-
Simulated Results
-
Actual Results
.webp?width=765&height=519&name=1736962717-elqquent1-2%20(1).webp)